Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

AACR 2020

27 - 28 Apr 2020

Published: 30 Jun 2020

Views: 767

Rating:

Save

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

Dr Haneen Shalabi speaks to ecancer in an online interview for the virtual AACR 2020 meeting.

She discusses the results of the phase 1 dose-escalation study evaluating the safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL.

Dr Shalabi goes through the background to the study and talks us through the methodology used.

She reports that the CAR T cells were well tolerated at all dose levels with a reversible side effect profile and patients did respond.

Related Videos

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows...

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )

Pembrrolizumab after chemotherapy demonstrates promising activity and...

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany

Pembrrolizumab after chemotherapy demonstrates promising activity and manageable safety in patients with low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

More from ecancer